Activin receptor‐like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes

Abstract Varieties of transforming growth factor‐β (TGF‐β) antagonists have been developed to intervene with excessive TGF‐β signalling activity in cancer. Activin receptor‐like kinase5 (ALK5) inhibitors antagonize TGF‐β signalling by blocking TGF‐β receptor‐activated Smad (R‐Smad) phosphorylation....

Description complète

Détails bibliographiques

Auteurs principaux:	Jeong‐Hwan Yoon, Su Myung Jung, Seok Hee Park, Mitsuyasu Kato, Tadashi Yamashita, In‐Kyu Lee, Katsuko Sudo, Susumu Nakae, Jin Soo Han, Ok‐Hee Kim, Byung‐Chul Oh, Takayuki Sumida, Masahiko Kuroda, Ji‐Hyeon Ju, Kyeong Cheon Jung, Seong Hoe Park, Dae‐Kee Kim, Mizuko Mamura
Format:	Artigo
Langue:	Inglês
Publié:	Springer Nature 2013-10-01
Collection:	EMBO Molecular Medicine
Sujets:	ALK5 inhibitor Eomes melanoma Smad4 TGF‐β
Accès en ligne:	https://doi.org/10.1002/emmm.201302524
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!